Ligand Historical Income Statement

LGND Stock

USD 121.47 1.08 0.88%

Historical analysis of Ligand Pharmaceuticals income statement accounts such as Gross Profit of 86.4 M can show how well Ligand Pharmaceuticals Incorporated performed in making a profits. Evaluating Ligand Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Ligand Pharmaceuticals's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Ligand Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Ligand Pharmaceuticals is a good buy for the upcoming year.

Net Income Gross Profit

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Ligand Pharmaceuticals Incorporated. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Ligand Income Statement Analysis

Ligand Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Ligand Pharmaceuticals shareholders. The income statement also shows Ligand investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Ligand Pharmaceuticals Income Statement Chart

At present, Ligand Pharmaceuticals' Operating Income is projected to increase significantly based on the last few years of reporting. The current year's EBIT is expected to grow to about 67.5 M, whereas Total Revenue is forecasted to decline to about 101.8 M.

Total Revenue Other Operating Expenses Selling General Administrative Non Recurring

Total Revenue

Total revenue comprises all receipts Ligand Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Ligand Pharmaceuticals. It is also known as Ligand Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Ligand Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Ligand Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Ligand Pharmaceuticals Incorporated. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	136.1M	140.4M	84.3M	97.9M
Cost Of Revenue	62.2M	52.8M	35.0M	19.3M

Total Operating Expenses Cost Of Revenue

Ligand Pharmaceuticals income statement Correlations

	Depreciation And Amortization	Interest Expense	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Research Development	Selling General Administrative	Selling And Marketing Expenses	Discontinued Operations	Net Income From Continuing Ops	Non Operating Income Net Other	Non Recurring	Tax Provision	Interest Income	Net Interest Income	Extraordinary Items	Reconciled Depreciation
Depreciation And Amortization		-0.44	0.05	0.01	-0.09	0.19	0.29	0.98	0.17	-0.18	-0.96	-0.98	-0.9	-0.57	-0.32	-0.02	-0.14	-0.04	-0.92	-0.36	-0.06	-0.43	-0.47	-0.07	-0.05	-0.37
Interest Expense	-0.44		0.62	0.72	0.31	0.65	0.54	-0.29	-0.08	0.43	0.57	0.43	0.56	0.28	0.45	0.27	0.3	-0.02	0.58	0.72	0.07	0.49	0.14	-0.67	-0.02	0.2
Total Revenue	0.05	0.62		0.98	0.81	0.61	0.75	0.2	0.6	0.82	0.16	0.02	0.09	0.2	0.63	0.78	0.03	-0.63	0.08	0.19	-0.25	0.65	-0.49	-0.31	-0.14	0.58
Gross Profit	0.01	0.72	0.98		0.71	0.72	0.81	0.18	0.42	0.76	0.2	0.05	0.15	0.2	0.54	0.69	0.05	-0.53	0.14	0.31	-0.23	0.66	-0.37	-0.41	-0.2	0.47
Other Operating Expenses	-0.09	0.31	0.81	0.71		0.05	0.33	-0.01	0.83	0.97	0.21	0.17	0.12	0.29	0.8	0.96	-0.15	-0.81	0.11	-0.18	-0.38	0.69	-0.59	0.13	0.01	0.85
Operating Income	0.19	0.65	0.61	0.72	0.05		0.89	0.36	-0.12	0.11	0.01	-0.18	0.02	-0.04	0.05	0.05	0.11	-0.02	0.02	0.55	-0.04	0.23	-0.05	-0.67	-0.26	-0.1
Ebit	0.29	0.54	0.75	0.81	0.33	0.89		0.47	0.14	0.37	-0.05	-0.22	-0.11	0.09	0.2	0.37	-0.22	-0.39	-0.13	0.32	-0.38	0.46	-0.28	-0.39	-0.23	0.17
Ebitda	0.98	-0.29	0.2	0.18	-0.01	0.36	0.47		0.19	-0.09	-0.9	-0.95	-0.85	-0.51	-0.26	0.06	-0.17	-0.12	-0.88	-0.26	-0.14	-0.3	-0.49	-0.14	-0.09	-0.31
Cost Of Revenue	0.17	-0.08	0.6	0.42	0.83	-0.12	0.14	0.19		0.69	-0.1	-0.1	-0.17	0.09	0.69	0.75	-0.12	-0.73	-0.16	-0.38	-0.23	0.33	-0.74	0.22	0.15	0.74
Total Operating Expenses	-0.18	0.43	0.82	0.76	0.97	0.11	0.37	-0.09	0.69		0.32	0.26	0.22	0.34	0.77	0.96	-0.17	-0.77	0.2	-0.09	-0.42	0.78	-0.47	0.09	-0.04	0.82
Income Before Tax	-0.96	0.57	0.16	0.2	0.21	0.01	-0.05	-0.9	-0.1	0.32		0.98	0.93	0.6	0.37	0.16	0.03	-0.13	0.94	0.47	-0.09	0.59	0.36	0.04	0.0	0.47
Total Other Income Expense Net	-0.98	0.43	0.02	0.05	0.17	-0.18	-0.22	-0.95	-0.1	0.26	0.98		0.91	0.6	0.34	0.12	0.01	-0.11	0.92	0.38	-0.07	0.52	0.38	0.16	0.06	0.47
Net Income	-0.9	0.56	0.09	0.15	0.12	0.02	-0.11	-0.85	-0.17	0.22	0.93	0.91		0.27	0.28	0.09	0.06	-0.03	0.99	0.56	-0.09	0.43	0.36	0.0	0.09	0.39
Income Tax Expense	-0.57	0.28	0.2	0.2	0.29	-0.04	0.09	-0.51	0.09	0.34	0.6	0.6	0.27		0.37	0.22	-0.02	-0.27	0.31	0.04	0.0	0.6	0.16	0.1	-0.18	0.39
Research Development	-0.32	0.45	0.63	0.54	0.8	0.05	0.2	-0.26	0.69	0.77	0.37	0.34	0.28	0.37		0.66	-0.01	-0.5	0.31	-0.04	-0.19	0.58	-0.33	-0.09	-0.01	0.75
Selling General Administrative	-0.02	0.27	0.78	0.69	0.96	0.05	0.37	0.06	0.75	0.96	0.16	0.12	0.09	0.22	0.66		-0.3	-0.86	0.06	-0.17	-0.52	0.71	-0.6	0.23	0.03	0.81
Selling And Marketing Expenses	-0.14	0.3	0.03	0.05	-0.15	0.11	-0.22	-0.17	-0.12	-0.17	0.03	0.01	0.06	-0.02	-0.01	-0.3		0.56	0.13	0.27	0.92	-0.31	0.21	-0.66	-0.07	-0.37
Discontinued Operations	-0.04	-0.02	-0.63	-0.53	-0.81	-0.02	-0.39	-0.12	-0.73	-0.77	-0.13	-0.11	-0.03	-0.27	-0.5	-0.86	0.56		0.01	0.19	0.7	-0.71	0.65	-0.48	0.1	-0.8
Net Income From Continuing Ops	-0.92	0.58	0.08	0.14	0.11	0.02	-0.13	-0.88	-0.16	0.2	0.94	0.92	0.99	0.31	0.31	0.06	0.13	0.01		0.57	-0.02	0.41	0.39	-0.05	0.08	0.36
Non Operating Income Net Other	-0.36	0.72	0.19	0.31	-0.18	0.55	0.32	-0.26	-0.38	-0.09	0.47	0.38	0.56	0.04	-0.04	-0.17	0.27	0.19	0.57		0.18	0.07	0.15	-0.59	-0.01	-0.16
Non Recurring	-0.06	0.07	-0.25	-0.23	-0.38	-0.04	-0.38	-0.14	-0.23	-0.42	-0.09	-0.07	-0.09	0.0	-0.19	-0.52	0.92	0.7	-0.02	0.18		-0.56	0.24	-0.58	0.03	-0.52
Tax Provision	-0.43	0.49	0.65	0.66	0.69	0.23	0.46	-0.3	0.33	0.78	0.59	0.52	0.43	0.6	0.58	0.71	-0.31	-0.71	0.41	0.07	-0.56		-0.06	0.21	-0.28	0.69
Interest Income	-0.47	0.14	-0.49	-0.37	-0.59	-0.05	-0.28	-0.49	-0.74	-0.47	0.36	0.38	0.36	0.16	-0.33	-0.6	0.21	0.65	0.39	0.15	0.24	-0.06		-0.12	0.08	-0.44
Net Interest Income	-0.07	-0.67	-0.31	-0.41	0.13	-0.67	-0.39	-0.14	0.22	0.09	0.04	0.16	0.0	0.1	-0.09	0.23	-0.66	-0.48	-0.05	-0.59	-0.58	0.21	-0.12		0.01	0.37
Extraordinary Items	-0.05	-0.02	-0.14	-0.2	0.01	-0.26	-0.23	-0.09	0.15	-0.04	0.0	0.06	0.09	-0.18	-0.01	0.03	-0.07	0.1	0.08	-0.01	0.03	-0.28	0.08	0.01		0.15
Reconciled Depreciation	-0.37	0.2	0.58	0.47	0.85	-0.1	0.17	-0.31	0.74	0.82	0.47	0.47	0.39	0.39	0.75	0.81	-0.37	-0.8	0.36	-0.16	-0.52	0.69	-0.44	0.37	0.15

Click cells to compare fundamentals

Ligand Pharmaceuticals Account Relationship Matchups

Ligand Pharmaceuticals income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	(798.8M)	28.0M	41.3M	43.4M	37.4M	39.3M
Interest Expense	35.7M	27.4M	18.7M	1.8M	656K	623.2K
Total Revenue	120.3M	186.4M	277.1M	196.2M	131.3M	101.8M
Gross Profit	108.9M	156M	215.0M	143.4M	96.3M	86.4M
Other Operating Expenses	126.0M	177.7M	198.2M	193.2M	119.4M	112.7M
Operating Income	(5.7M)	8.6M	78.9M	(25.5M)	11.9M	12.5M
Ebit	(5.7M)	41.1M	91.8M	11.0M	64.3M	67.5M
Ebitda	(804.5M)	69.1M	133.2M	54.4M	101.7M	106.8M
Cost Of Revenue	11.3M	30.4M	62.2M	52.8M	35.0M	19.3M
Total Operating Expenses	114.7M	147.3M	136.1M	140.4M	84.3M	97.9M
Income Before Tax	796.6M	(10.5M)	47.3M	36.0M	63.7M	66.8M
Total Other Income Expense Net	802.4M	(36.4M)	(31.6M)	33.0M	51.7M	54.3M
Net Income	629.3M	(3.0M)	57.1M	(5.2M)	52.2M	54.8M
Income Tax Expense	167.3M	(7.6M)	(10.3M)	41.2M	9.8M	6.5M
Research Development	55.9M	59.4M	69.0M	36.1M	24.5M	33.6M
Selling General Administrative	41.9M	64.4M	57.5M	70.1M	52.8M	49.7M
Net Income From Continuing Ops	629.3M	(3.0M)	57.6M	(5.2M)	21.1M	20.0M
Non Operating Income Net Other	57.9M	25.3M	(9.0M)	(12.0M)	(13.8M)	(13.1M)
Net Income Applicable To Common Shares	629.3M	(3.0M)	57.6M	(33.4M)	(38.4M)	(36.4M)
Tax Provision	167.3M	(7.6M)	(10.3M)	41.2M	49.6M	52.1M
Interest Income	28.4M	8.1M	886K	2.0M	7.0M	11.2M
Net Interest Income	(7.3M)	(19.3M)	(18.7M)	247K	6.3M	6.6M
Reconciled Depreciation	43.7M	28.0M	47.2M	34.2M	37.9M	34.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft

When determining whether Ligand Pharmaceuticals is a strong investment it is important to analyze Ligand Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ligand Pharmaceuticals' future performance. For an informed investment choice regarding Ligand Stock, refer to the following important reports:

How To Invest In Ligand

Details

Is Ligand Stock a good investment?

Details

What is Ligand Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ligand Pharmaceuticals. If investors know Ligand will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ligand Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

1.032

Earnings Share

2.49

Revenue Per Share

8.509

Quarterly Revenue Growth

0.576

Return On Assets

0.013

The market value of Ligand Pharmaceuticals is measured differently than its book value, which is the value of Ligand that is recorded on the company's balance sheet. Investors also form their own opinion of Ligand Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ligand Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ligand Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ligand Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Ligand Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ligand Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ligand Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Ligand Historical Income Statement

About Ligand Income Statement Analysis

Ligand Pharmaceuticals Income Statement Chart

Total Revenue

Other Operating Expenses

Ligand Pharmaceuticals income statement Correlations

Ligand Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Ligand Pharmaceuticals income statement Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Income From Continuing Ops	+ 0.99	Net Income
Ebitda	+ 0.98	Depreciation And Amortization
Gross Profit	+ 0.98	Total Revenue
Total Other Income Expense Net	+ 0.98	Income Before Tax
Total Operating Expenses	+ 0.97	Other Operating Expenses
Selling General Administrative	+ 0.96	Other Operating Expenses

Total Other Income Expense Net	- 0.98	Depreciation And Amortization
Income Before Tax	- 0.96	Depreciation And Amortization
Total Other Income Expense Net	- 0.95	Ebitda
Net Income From Continuing Ops	- 0.92	Depreciation And Amortization
Income Before Tax	- 0.9	Ebitda
Net Income	- 0.9	Depreciation And Amortization